ES2078654T3 - Analogos de atp. - Google Patents
Analogos de atp.Info
- Publication number
- ES2078654T3 ES2078654T3 ES92302927T ES92302927T ES2078654T3 ES 2078654 T3 ES2078654 T3 ES 2078654T3 ES 92302927 T ES92302927 T ES 92302927T ES 92302927 T ES92302927 T ES 92302927T ES 2078654 T3 ES2078654 T3 ES 2078654T3
- Authority
- ES
- Spain
- Prior art keywords
- alkyl
- alkoxy
- halogen
- aryl
- optionally substituted
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
- 125000000217 alkyl group Chemical group 0.000 abstract 4
- 125000003545 alkoxy group Chemical group 0.000 abstract 3
- 229910052736 halogen Inorganic materials 0.000 abstract 3
- 150000002367 halogens Chemical class 0.000 abstract 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 2
- 125000003118 aryl group Chemical group 0.000 abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract 2
- 239000001257 hydrogen Substances 0.000 abstract 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 2
- 230000002378 acidificating effect Effects 0.000 abstract 1
- 125000004442 acylamino group Chemical group 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 125000000623 heterocyclic group Chemical group 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/28—Phosphorus compounds with one or more P—C bonds
- C07F9/38—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
- C07F9/3804—Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
- C07F9/3808—Acyclic saturated acids which can have further substituents on alkyl
- C07F9/3821—Acyclic saturated acids which can have further substituents on alkyl substituted by B, Si, P or a metal
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Mechanical Treatment Of Semiconductor (AREA)
- Medicinal Preparation (AREA)
- Color Television Image Signal Generators (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Un procedimiento para la producción de un compuesto de la fórmula I en la que Q representa CR 1 R 2 , R representa O o CR 3 R 4 , W representa O o CH2, R 1 , R 2 , R 3 y R 4 representan independientemente hidrógeno o halógeno, X representa S(O)nR 5 , n representa 0,1ó 2, R 5 representa etilo, butilo o propilo, Y representa NH2 o alcoxiC1-6, y Z representa una porción ácida, además: a) cuando R representa CR 3 R 4 , entonces Q Z pueden representar hidroxi o OP(O)(OH)2; y b) cuando R y W representan O, Q representa CCl2 o CBr2, Y representa NH2 y Z representa P(O)(OH)2, entonces X puede representar S pentilo; o una de sus sales farmacéuticamente aceptable, cuyo proceso comprende: a) producir un compuesto de la fórmula I en el que R representa O o una de sus sales, haciendo reaccionar un compuesto de la fórmula II o una de sus sales donde W, X e Y son como se ha definido anteriormente y L1 representa un grupo lábil con un compuesto de la fórmula III o una de sus sales, O k Z -Q -P-OH j OH IIIdonde Z y Q son como se ha definido anteriormente; b) producir un compuesto de la fórmula I en la que R representa CR 3 R 4 , o una de sus sales, haciendo reaccionar un compuesto de la fórmula IV o una de sus sales, donde W, X e Y son como se ha definido anteriormente y L2 representa un grupo lábil con un compuesto de la fórmula V o una de sus sales, O O k k Z -Q -P -CR 3 R 4 -P OH j j OH OH V donde Z, Q, R 3 y R 4 son como se ha definido anteriormente; c) producir un compuesto de la fórmula I en el que R es CR 3 R 4 y Q Z es OP(O)(OH)2, o una de sus sales, haciendo reaccionar un compuesto de la fórmula I en la que Q Z es hidroxi con un compuesto de la fórmula VI o una de sus sales O k L3 -P OH j OH VI donde L3 es un grupo lábil; y d) separación de un grupo protector de un compuesto correspondiente protegido de la fórmula I en la que uno o más de los grupos funcionales está protegido, y cuando se desee o sea necesario convertir el compuesto resultante de la fórmula I u otra sal del mismo enuna de sus sales farmacéuticamente aceptable o viceversa.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB919107236A GB9107236D0 (en) | 1991-04-06 | 1991-04-06 | Compounds |
| GB919123671A GB9123671D0 (en) | 1991-11-07 | 1991-11-07 | Compounds |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2078654T3 true ES2078654T3 (es) | 1995-12-16 |
Family
ID=26298696
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES92302927T Expired - Lifetime ES2078654T3 (es) | 1991-04-06 | 1992-04-02 | Analogos de atp. |
Country Status (18)
| Country | Link |
|---|---|
| EP (2) | EP0579643A1 (es) |
| JP (1) | JP3141028B2 (es) |
| CN (2) | CN1031879C (es) |
| AT (1) | ATE127808T1 (es) |
| CA (1) | CA2107667A1 (es) |
| DE (1) | DE69204717T2 (es) |
| DK (1) | DK0508687T3 (es) |
| ES (1) | ES2078654T3 (es) |
| FI (1) | FI934366A0 (es) |
| GR (1) | GR3018307T3 (es) |
| HU (2) | HUT64967A (es) |
| IE (1) | IE921091A1 (es) |
| IL (1) | IL101485A0 (es) |
| MX (1) | MX9201577A (es) |
| NO (1) | NO933555L (es) |
| NZ (1) | NZ242243A (es) |
| PL (1) | PL297372A1 (es) |
| WO (1) | WO1992017488A1 (es) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5760021A (en) * | 1992-05-29 | 1998-06-02 | The Procter & Gamble Company | Phosphonocarboxylate compounds pharmaceutical compositions, and methods for treating abnormal calcium and phosphate metabolism |
| US5731299A (en) * | 1992-05-29 | 1998-03-24 | The Procter & Gamble Company | Phosphonosulfonate compounds, pharmaceutical compositions, and methods for treating abnormal calcium and phosphate metabolism |
| EP0683789B1 (en) * | 1993-02-10 | 1997-11-05 | Astra Pharmaceuticals Limited | N-alkyl-2-substituted atp analogues |
| FR2721929B1 (fr) * | 1994-06-30 | 1996-12-20 | Centre Nat Rech Scient | Analogues stables, non hydrolysables, de diphosphates et leurs procedes de preparation |
| EP0929218A4 (en) * | 1996-10-30 | 2001-05-16 | Univ North Carolina | R2Y RECEPTOR ANTAGONISTS |
| US6159952A (en) * | 1996-11-07 | 2000-12-12 | Inspire Pharmaceuticals, Inc. | Method of treating bronchitis with uridine triphosphate and related compounds |
| US6686462B2 (en) * | 1997-02-28 | 2004-02-03 | The Regents Of The University Of California | Antiviral compounds and methods of administration |
| FI104901B (fi) | 1997-10-20 | 2000-04-28 | Leiras Oy | Uudet metyleenibisfosfonihappojohdannaiset |
| US6667306B1 (en) | 1998-01-15 | 2003-12-23 | Millennium Pharmaceuticals, Inc. | Platelet ADP receptor inhibitors |
| TWI229674B (en) | 1998-12-04 | 2005-03-21 | Astra Pharma Prod | Novel triazolo[4,5-d]pyrimidine compounds, pharmaceutical composition containing the same, their process for preparation and uses |
| CN1166677C (zh) * | 1999-06-22 | 2004-09-15 | Cv治疗公司 | 噻吩a2a受体激动剂 |
| SE9903290D0 (sv) * | 1999-09-15 | 1999-09-15 | Astra Pharma Prod | Novel compounds |
| SE9904377D0 (sv) * | 1999-12-01 | 1999-12-01 | Astra Pharma Prod | Pharmaceutical combinations |
| GB0013488D0 (en) * | 2000-06-02 | 2000-07-26 | Astrazeneca Ab | Chemical compound |
| US7452870B2 (en) | 2000-08-21 | 2008-11-18 | Inspire Pharmaceuticals, Inc. | Drug-eluting stents coated with P2Y12 receptor antagonist compound |
| US7132408B2 (en) | 2000-08-21 | 2006-11-07 | Inspire Pharmaceuticals, Inc. | Composition and method for inhibiting platelet aggregation |
| US6897201B2 (en) | 2000-08-21 | 2005-05-24 | Inspire Pharmaceuticals, Inc. | Compositions and methods for the treatment of glaucoma or ocular hypertension |
| US7115585B2 (en) | 2000-08-21 | 2006-10-03 | Inspire Pharmaceuticals, Inc. | Compositions for treating epithelial and retinal tissue diseases |
| US7018985B1 (en) | 2000-08-21 | 2006-03-28 | Inspire Pharmaceuticals, Inc. | Composition and method for inhibiting platelet aggregation |
| US7435724B2 (en) | 2002-02-27 | 2008-10-14 | Inspire Pharmaceutical, Inc. | Degradation-resistant mononucleoside phosphate compounds |
| SE0401001D0 (sv) * | 2004-03-31 | 2004-03-31 | Astrazeneca Ab | Chemical process |
| US20100048501A1 (en) | 2006-03-21 | 2010-02-25 | Heinrich-Heine-Universitat Dusseldorf | Phosphorylated A2A Receptor Agonists |
| JP6577165B2 (ja) * | 2011-01-26 | 2019-09-18 | 北京康倍得医▲藥▼技▲術▼▲開▼▲發▼有限公司 | リボフラノシルプリン化合物、その調製方法、およびその使用 |
| CN102659691B (zh) * | 2012-05-23 | 2014-04-02 | 山东诚创医药技术开发有限公司 | 一种4,6-二氯-5-氨基-2-丙硫基嘧啶的制备方法 |
| CN103288748A (zh) * | 2013-06-21 | 2013-09-11 | 四川铂瑞生物医药有限公司 | 一种4.6-二氯-5-氨基-2-丙硫基嘧啶的制备方法 |
| CN104003943A (zh) * | 2014-05-06 | 2014-08-27 | 南通常佑药业科技有限公司 | 一种替格瑞洛中间体的制备方法 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2049977A1 (en) * | 1989-03-24 | 1990-09-25 | Hirofumi Kitaoka | Nootropic agent |
-
1992
- 1992-04-02 CA CA002107667A patent/CA2107667A1/en not_active Abandoned
- 1992-04-02 WO PCT/GB1992/000590 patent/WO1992017488A1/en not_active Application Discontinuation
- 1992-04-02 EP EP92907588A patent/EP0579643A1/en active Pending
- 1992-04-02 PL PL29737292A patent/PL297372A1/xx unknown
- 1992-04-02 AT AT92302927T patent/ATE127808T1/de not_active IP Right Cessation
- 1992-04-02 HU HU9302812A patent/HUT64967A/hu unknown
- 1992-04-02 JP JP04506961A patent/JP3141028B2/ja not_active Expired - Fee Related
- 1992-04-02 DK DK92302927.6T patent/DK0508687T3/da active
- 1992-04-02 ES ES92302927T patent/ES2078654T3/es not_active Expired - Lifetime
- 1992-04-02 EP EP92302927A patent/EP0508687B1/en not_active Expired - Lifetime
- 1992-04-02 DE DE69204717T patent/DE69204717T2/de not_active Expired - Fee Related
- 1992-04-03 IL IL101485A patent/IL101485A0/xx unknown
- 1992-04-06 IE IE109192A patent/IE921091A1/en unknown
- 1992-04-06 MX MX9201577A patent/MX9201577A/es unknown
- 1992-04-06 NZ NZ242243A patent/NZ242243A/xx unknown
- 1992-04-06 CN CN92103371A patent/CN1031879C/zh not_active Expired - Fee Related
-
1993
- 1993-10-05 NO NO93933555A patent/NO933555L/no unknown
- 1993-10-05 FI FI934366A patent/FI934366A0/fi not_active Application Discontinuation
-
1995
- 1995-06-13 HU HU95P/P00190P patent/HU211334A9/hu unknown
- 1995-08-05 CN CN95109290A patent/CN1120936A/zh active Pending
- 1995-12-05 GR GR950403426T patent/GR3018307T3/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP3141028B2 (ja) | 2001-03-05 |
| WO1992017488A1 (en) | 1992-10-15 |
| AU648885B2 (en) | 1994-05-05 |
| FI934366A (fi) | 1993-10-05 |
| HUT64967A (en) | 1994-03-28 |
| JPH06505987A (ja) | 1994-07-07 |
| HU9302812D0 (en) | 1993-12-28 |
| EP0508687A1 (en) | 1992-10-14 |
| IE921091A1 (en) | 1992-10-07 |
| PL297372A1 (en) | 1993-09-06 |
| NO933555D0 (no) | 1993-10-05 |
| CN1031879C (zh) | 1996-05-29 |
| EP0508687B1 (en) | 1995-09-13 |
| EP0579643A1 (en) | 1994-01-26 |
| MX9201577A (es) | 1992-10-01 |
| ATE127808T1 (de) | 1995-09-15 |
| AU1451992A (en) | 1992-11-02 |
| NO933555L (no) | 1993-10-05 |
| CA2107667A1 (en) | 1992-10-07 |
| NZ242243A (en) | 1993-06-25 |
| DE69204717D1 (de) | 1995-10-19 |
| CN1068574A (zh) | 1993-02-03 |
| CN1120936A (zh) | 1996-04-24 |
| DK0508687T3 (da) | 1996-02-05 |
| GR3018307T3 (en) | 1996-03-31 |
| FI934366A0 (fi) | 1993-10-05 |
| DE69204717T2 (de) | 1996-04-25 |
| HU211334A9 (en) | 1995-11-28 |
| IL101485A0 (en) | 1992-12-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2078654T3 (es) | Analogos de atp. | |
| FI104172B1 (fi) | Herbisidiset 4-bentsoyyli-isoksatsolijohdannaiset | |
| ES474215A1 (es) | Procedimiento para la preparacion de derivados imidazolile- tiloxialcoxilicos y sus analogos con agrupacion tio | |
| NO921159D0 (no) | Tiazolidinon- og oksazolidinonderivater, fremgangsmaate til fremstilling derav, samt anvendelse av derivatene som vasodilatorer | |
| DK169989D0 (da) | Heterocyclisk substituerede alkyl- og alkenylsulfonylurinstoffer, fremgangsmaader til deres fremstilling samt deres anvendelse som herbicider og plantevaekstregulerende midler | |
| AU4271389A (en) | Phenylalkyl or phenylalkoxyethyl substituted piperazine derivatives | |
| FI860145A (fi) | Herbicider av typ n-(fosfonometylglycyl)sulfonylaminer. | |
| BR8003950A (pt) | Composicoes herbicidas, baseadas em derivados de m-anilido-uretana | |
| DE69208384T2 (de) | Fungizide Furanonderivate |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG2A | Definitive protection |
Ref document number: 508687 Country of ref document: ES |